

# EUR Research Information Portal

## Regulation of intra-tumoral T cell immunity in liver cancer

### Publication status and date:

Published: 04/07/2018

### Document Version

Other version

### Citation for the published version (APA):

Zhou, G. (2018). *Regulation of intra-tumoral T cell immunity in liver cancer*. [Doctoral Thesis, Erasmus University Rotterdam]. Erasmus Universiteit Rotterdam (EUR).

[Link to publication on the EUR Research Information Portal](#)

### Terms and Conditions of Use

Except as permitted by the applicable copyright law, you may not reproduce or make this material available to any third party without the prior written permission from the copyright holder(s). Copyright law allows the following uses of this material without prior permission:

- you may download, save and print a copy of this material for your personal use only;
- you may share the EUR portal link to this material.

In case the material is published with an open access license (e.g. a Creative Commons (CC) license), other uses may be allowed. Please check the terms and conditions of the specific license.

### Take-down policy

If you believe that this material infringes your copyright and/or any other intellectual property rights, you may request its removal by contacting us at the following email address: [openaccess.library@eur.nl](mailto:openaccess.library@eur.nl). Please provide us with all the relevant information, including the reasons why you believe any of your rights have been infringed. In case of a legitimate complaint, we will make the material inaccessible and/or remove it from the website.

## Propositions

### To the thesis

#### *Regulation of intra-tumoral T cell immunity in liver cancer*

By Guoying Zhou

1. HCC TIL that express co-inhibitory receptors may be tumor-reactive T cells, which continue upregulating these receptors in response to chronic stimulation by tumor antigens to prevent further over activation, and thereby are subsequently inhibited by interactions of these receptors with their ligands. (This thesis)
2. The difference in responsiveness to PD-1/PD-L1 blockade between MMR-deficient and MMR-proficient CRC may relate to MMR-deficient tumors containing higher numbers of mutations, which result in more mutation-encoded neo-antigens, thereby eliciting stronger anti-tumor T cell responses. (This thesis)
3. The small proportion of LAG3<sup>+</sup> TIL in LM-CRC may be enriched with tumor antigen-specific T cells, which are known to constitute only a small proportion of TIL, while PD-1 is expressed on a larger fraction of TIL which might contain more non-tumor-specific T cells. (This thesis)
4. Foxp3<sup>+</sup> Treg are both inside the tumor and at tumor margin of cholangiocarcinoma, but CD8<sup>+</sup> T cells are predominantly sequestered at tumor margin, suggesting that tumors may suppress immigration of cytotoxic immune cells, which is a way of immune evasion. (This thesis)
5. The reported functional effects of antibodies on effector T cells in our *ex vivo* assays may be partly indirect, mediated by immune suppressor cells, and the effects of some antibodies on effector T cells might even be counteracted by their effects on suppressor cells. (This thesis)
6. Shoot for the moon. Even if you miss it you will land among the stars. --Les Brown
7. Everything is theoretically impossible, until it is done. --Robert A. Heinlein
8. Research is what I'm doing when I don't know what I'm doing. --Wernher von Braun
9. Medicine is a science of uncertainty and an art of probability. --William Osler
10. Opportunities come to those who are prepared.
11. No pain, no gain.